acalabrutinib maleate monohydrate
(uh-KA-luh-BROO-tih-nib MAY-lee-AYT MAH-noh-HY-drayt)
A drug used alone to treat adults with chronic lymphocytic leukemia or small lymphocytic lymphoma and adults with mantle cell lymphoma that has already been treated with at least one other therapy. Acalabrutinib maleate monohydrate is used with bendamustine and rituximab to treat adults with mantle cell lymphoma that has not been treated and who cannot receive an autologous stem cell transplant. It is also being studied in the treatment of other types of cancer. Acalabrutinib maleate monohydrate blocks a protein called BTK, which may help keep cancer cells from growing. It is a type of tyrosine kinase inhibitor. Also called Calquence.